From WikiProjectMed
Jump to navigation Jump to search
Trade namesFilspari
Clinical data
Drug classEndothelin and angiotensin II receptor blocker[1]
Main usesPrimary immunoglobulin A nephropathy.[1]
Side effectsLow blood pressure, swelling of the legs, high potassium, low red blood cells, liver problems[1]
Routes of
By mouth
Typical dose200 to 400 mg OD[1]
External links
License data
Legal status

Sparsentan, sold under the brand name Filspari, is a medication used to treat primary immunoglobulin A nephropathy.[1] Specifically it is used to reduce protein in the urine.[1] As of 2023, it is unclear if it affects long term kidney function.[1] It is taken by mouth.[1]

Common side effects include low blood pressure, swelling of the legs, high potassium, and low red blood cells.[1] Severe side effects may include liver problems.[1] Use in pregnancy may harm the baby.[1] It is an endothelin and angiotensin II receptor blocker.[1]

Sparsentan was approved for medical use in the United States in 2023.[1] It is estimated to cost about 170,000 USD per year in the United States as of 2023.[2]

Medical uses

Sparsentan is indicated to reduce proteinuria in people with primary immunoglobulin A nephropathy.[1]


It is started at 200 mg once per day and is increased to 400 mg once per day after two weeks.[1]

Society and culture

Legal status

Sparsentan is approved in the US under accelerated approval based on reduction of proteinuria.[1]


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 "Filspari- sparsentan tablet, film coated". DailyMed. 17 February 2023. Archived from the original on 7 March 2023. Retrieved 6 March 2023.
  2. "February 2023 decisions expected from the FDA". Prime Therapeutics LLC. Archived from the original on 27 January 2023. Retrieved 24 May 2023.

External links

  • Clinical trial number NCT03762850 for "A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)" at